UnicoCell
向榮生醫科技股份有限公司
UnicoCell is a Taiwan TWSE-listed biotechnology company; its most advanced asset is ELIXCYTE-CKD (Phase 1/2 completed; Phase 3 IND submitted, Chronic kidney disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ELIXCYTE-CKD | — | Phase 1/2 completed; Phase 3 IND submitted | Chronic kidney disease | United States (Phase 3 application) | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.